Q-omics provides the consensus-scored TRIM55 profile across patient tissues and cancer cell-line models. TRIM55 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRIM55 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, TRIM55 RNA expression shows 15,345 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight SKCM, KIRC, and HNSC as cancer lineages where TRIM55 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM55 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM55 survival associations across molecular data types. TRIM55 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM55 RNA expression–survival associations across cancer types. High TRIM55 expression shows favorable associations in SKCM, KIRP, BLCA, KIRC, LIHC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRIM55 RNA expression.
This table summarizes TRIM55 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TRIM55. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM55 shows lower tumor expression in KICH, HNSC, LUSC, COAD and KIRP and higher tumor expression in KIRC. The KIRC box plot shows higher TRIM55 RNA expression in tumor versus normal tissue (log2 FC = +1.417, t-test p < 0.001).
This table shows molecular features associated with TRIM55 in patient tissues and cancer cell lines. In patient samples, TRIM55 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM55 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
